The lack of involvement of central nervous system in the antiarrhythmic effects of prostaglandins E2, F2 alpha, and I2 in cat

T S RaoU Nayar


The role of the central nervous system (CNS) in the antiarrhythmic effects of prostaglandins (PGs) E2, F2 alpha, and I2 was studied by administering each agent into the left lateral cerebral ventricle (i.c.v. administration) of chloralose-anaesthetized cats. The cardiac arrhythmias were produced by intravenous (i.v.) infusion of ouabain (1 microgram/kg/min). The PGs E2, F2 alpha and I2 on i.c.v. administration in the dose range of 1 ng to 10 micrograms failed to inhibit ouabain-induced cardiac arrhythmias. However, when infused i.v., PGE2 (1 microgram/kg/min), PGF2 alpha (5 micrograms/kg/min), and PGI2 (2 micrograms/kg/min) effectively suppressed these arrhythmias. The standard antiarrhythmic drug propranolol (0.5-8.0 mg) on i.c.v. administration also significantly reduced the ouabain-induced cardiac arrhythmias. It is suggested that the CNS is not the site of action of PGs E2, F2 alpha, and I2 in antagonising the ouabain-induced cardiotoxicity in cats.


Jan 1, 1977·Annual Review of Pharmacology and Toxicology·P Hedqvist
Jun 1, 1976·The American Journal of Cardiology·B LevittR Gillis
Mar 1, 1973·European Journal of Pharmacology·S BergströmK Fuxe
Jan 1, 1973·Revista portuguesa de pediatria·M C Patuleia
Jun 1, 1973·Prostaglandins·W FörsterP Mentz
Dec 1, 1973·European Journal of Pharmacology·G J Kelliher, T M Glenn
Jul 1, 1970·British Journal of Pharmacology·H A LaveryG C Scroop
Nov 1, 1980·British Journal of Pharmacology·K Hillier, W W Templeton
Jul 20, 1983·The American Journal of Cardiology·J Staszewska-Barczak
Nov 1, 1983·Canadian Journal of Physiology and Pharmacology·M Karmazyn, N S Dhalla
Jan 1, 1983·General Pharmacology·E K Chiu, J S Richardson
Mar 1, 1983·Prostaglandins, Leukotrienes, and Medicine·H J Mest, J Rausch
Nov 1, 1981·Prostaglandins and Medicine·H J Mest, W Förster
Dec 1, 1980·Digestive Diseases and Sciences·D Rachmilewitz
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·A MORALES AGUILERA, E M VAUGHANWILLIAMS


Mar 11, 2005·Autonomic & Autacoid Pharmacology·A Tuncay Demiryürek, S Demiryürek

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.